Research Papers:

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Sarah Bertoli, Arthur Sterin, Suzanne Tavitian, Lucie Oberic, Loïc Ysebaert, Reda Bouabdallah, François Vergez, Audrey Sarry, Emilie Bérard, Françoise Huguet, Guy Laurent, Thomas Prébet, Norbert Vey and Christian Récher _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:85937-85947. https://doi.org/10.18632/oncotarget.13262

Metrics: PDF 1924 views  |   HTML 2321 views  |   ?  


Sarah Bertoli1,2,3, Arthur Sterin4, Suzanne Tavitian1, Lucie Oberic1, Loïc Ysebaert1,2,3, Reda Bouabdallah4, François Vergez3,5 , Audrey Sarry1, Emilie Bérard6,7, Françoise Huguet1, Guy Laurent1,2, Thomas Prébet4,8, Norbert Vey4,8,9,*, Christian Récher1,2,3,*

1Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

2Université Toulouse III Paul Sabatier, Toulouse, France

3Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France

4Service d’Hématologie, Institut Paoli-Calmettes, Marseille, France

5Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

6Service d’Epidémiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

7UMR 1027, INSERM-Université de Toulouse III, Toulouse, France

8Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, UMR1068 Inserm, Marseille, France

9Aix-Marseille University, Marseille, France

*co-senior authors

Correspondence to:

Christian Récher, email: [email protected]

Keywords: leukemia, therapy-related acute myeloid leukemia, second cancer, lymphoma, chronic lymphocytic leukemia

Received: May 26, 2016     Accepted: November 01, 2016     Published: November 10, 2016


Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13262